Zolgensma’s Success in SMA Treatment Advocates for AAV-based Gene Therapy and Promises a Bright Future for Genetic Disorders
At the 2023 Muscular Dystrophy Association Clinical and Scientific Conference, Novartis presented new data highlighting the continued efficacy and durability of its gene therapy treatment, Zolgensma, in treating spinal muscular atrophy (SMA). Zolgensma has been shown...
International Rare Disease Day | PackGene GMP plasmid is DMF registered, helping drug applications and shining lights on rare disease therapy!
February 28th is the 16th International Rare Disease Day with the theme of "Shine lights on your life" . Rare diseases, also known as "orphan diseases", have a low incidence rate and multiple disease types. Most of them are chronic, lifelong, severe, and...
PackGene Biotech Inc. Breaks Ground on cGMP Biomanufacturing and Process Development Facility in Houston
Full-service operations center marks U.S. expansion for global CRO and CDMO Houston, TX, February 22, 2023 – PackGene Biotech Inc. (PackGene), a world-leading adeno-associated viral (rAAV) vector contract research organization (CRO) and contract development and...
The leading domestic gene therapy CDMO company PackGene completed a pre-C round of financing of hundreds of millions to accelerate the expansion of rAAV’s large-scale production capacity
PackGene Biotechnology Closes everal hundred million yuan preC Financing to Accelerate the expansion of rAAV's large-scale production Platform In April 2021, Guangzhou PackGene Biotechnology Co., Ltd. A leading CDMO company in chinese gene therapy area - announced the...
Strategic cooperation丨PackGene and Pall work together to create the future of gene therapy
On February 23, 2021, PackGene and Pall Co., Ltd. signed a strategic cooperation agreement. The two parties have carried out close cooperation on large-scale AAV production based on gene therapy, empowered the process platform, and jointly provided more efficient...
PackGene received B+ round of financing led by Sequoia China and co-invested by Decheng Capital
In October 2020,, Guangzhou PackGene Biotechnology Co., Ltd. (PackGene), an integrated solution provider focusing on AAV vector packaging and gene therapy CDMO, announced the completion of a new round of B+ round of financing, which was led by Sequoia China, followed...
PackGene received tens of millions of B round investment from Cathay Capital and Oriza Seed—help to accelerate the upgrading of Chinese gene therapy industry
Core Reminder: In August 2020, Guangzhou PackGene Biotech Co., Ltd. ("PackGene"), a well-known provider of integrated CDMO solutions and AAV vector packaging for gene therapy, announced the completion of the B round of tens of millions yuan in financing. In August...
Nature Communications & Nature Neuroscience | PackGene helps the cutting-edge AAV-based researches development
1. PackGene AAV helped the research of using AAVR to identify different mechanisms of AAV serotypes Adeno-associated virus (adeno-associated virus, AAV) belongs to the Parvoviridae dependent virus genus. It has the advantages of good safety, wide tropism, can infect...
PackGene Biotech has completed tens of millions of A round of financing-to promote the industrialization of gene therapy
A round of financing In February 2020, Guangzhou PackGene Biotech Co., Ltd. (hereinafter referred to as "PackGene") completed the A round of financing invested by Tengye Ventures. In the future, PackGene will continue to promote the technological innovation of viral...